Ixchiq HCP

Menu
Menu

References

  1. IXCHIQ® Product Monograph. January 14, 2026.
  2. IXCHIQ® Data on File. 2024.
  3. World Health Organization. Chikungunya. Published April 14, 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/chikungunya. Accessed August 26, 2025.
  4. Craig J, et al. Diagnostic challenges in chikungunya infection. CCDR. 2015;41(1):6–10.
  5. World Health Organization. Chikungunya Overview. Available at: https://www.who.int/health-topics/chikungunya#tab=tab_1. Accessed August 26, 2025.
  6. Thiberville SD, et al. Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy. Antivir Res. 2013 ;99(3):345–370.
  7. Sahadeo N, et al. Molecular Characterisation of chikungunya virus infections in Trinidad and comparison of clinical and laboratory features with dengue and other acute febrile cases. PLoS Negl Trop Dis. 2015;9(11):e0004199.
  8. European Centre for Disease Prevention and Control. 12-month Chikungunya virus disease case notification rate per 100 000 population, February 2025 to January 2026. Available at: https://www.ecdc.europa.eu/en/publications-data/12-month-chikungunya-virus-disease-case-notification-rate-100-000-population-9. Accessed March 11, 2026.
  9. World Health Organization. Chikungunya virus disease- Global situation. Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON581. Accessed October 8, 2025.
  10. Puntasecca CJ, King CH, LaBeaud AD. Measuring the global burden of chikungunya and Zika viruses: A systematic review. PLoS Negl Trop Dis. 2021;15(3):e0009055.
  11. de Souza, et al. Pathophysiology of chikungunya virus infection associated with fatal outcomes. Cell Host Microbe. 2024;32:606–622.
  12. European Centre for Disease Prevention and Control. Chikungunya worldwide overview. Available at: https://www.ecdc.europa.eu/en/chikungunya-monthly. Accessed August 26, 2025.
  13. Public Health Agency of Canada, BCCDC Public Health Laboratory, Alberta Precision Laboratories, Public Health Ontario Laboratory. Can Commun Dis Rep. 2025;51(9):374.
  14. Suhrbier A. Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat Rev. 2019;15:597–611.
  15. Centers for Disease Control and Prevention. Chikungunya in China. Available at: https://wwwnc.cdc.gov/travel/notices/level2/chikungunya-china. Accessed August 26, 2025.
  16. Centers for Disease Control and Prevention. Chikungunya in Cuba. Available at: https://wwwnc.cdc.gov/travel/notices/level2/chikungunya-cuba. Accessed November 3, 2025.
  17. Pan American Health Organization. Chikungunya: analysis by country. Available at: https://www.paho.org/en/arbo-portal/chikungunya-data-and-analysis/chikungunya-analysis-country. Accessed January 26, 2026.
  18. Staples JE, Hills S, Powers A. Chapter 4: Chikungunya/ In: Nemhauser J, ed. CDC Yellow Book 2026. Centers for Disease Control and Prevention. Available at:. https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/chikungunya. Accessed February 10, 2026.
  19. Nemg Simo FB, et al. Chikungunya virus diagnosis: A review of current antigen detection methods. Trop Med Infect Dis. 2023;8(7):365.
  20. Pathak H, et al. Chikungunya arthritis. Clin Med. 2019;19(5):381–385.
  21. Silva L, Dermody T. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737–749.
  22. Paixão ES, et al. Chikungunya chronic disease: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2018;1123(7):301–316.
  23. Marques CDL, et al. Recommendations of the Brazilian Society of Rheumatology for diagnosis and treatment of Chikungunya fever. Part 1 – Diagnosis and special situations. Rev Bras Reumatol. 2017;57(S2):S421–S437.
  24. Essackjee K, et al. Prevalence of and risk factors for chronic arthralgia and rheumatoid-like polyarthritis more than 2 years after infection with chikungunya virus. Postgrad Med J. 2013;89(1054):440–447.
  25. World Health Organization. Guidelines on Clinical Management of Chikungunya Fever. Published October 2008. Accessed July 25, 2024. Available at: https://iris.who.int/bitstream/handle/10665/205178/B3234.pdf?sequence=1.
  26. De Roo AM, et al. The global health and economic burden of chikungunya from 2011 to 2020: a model-driven analysis on the impact of an emerging vector-borne disease. BMJ Glob Health. 2024;9:1–11.
  27. Buerger V., et al. Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil. Lancet Infect Dis. 2025.
  28. Schneider M., et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: A double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. 2023;401:2138–2147.
  29. Centers for Disease Control and Prevention. Factors to assess when considering use of chikungunya vaccine. Updated May 15, 2024. Accessed July 19, 2024. Available at: https://www.cdc.gov/chikungunya/media/pdfs/2024/05/Chikungunya-vaccine-risk-factors-508.pdf.
  30. Boggild AK. et al. Chikungunya in travellers returning to Canada: Surveillance report from CanTravNet surveillance data, 2006 to 2015. J Assoc Med Microbiol Infect Dis Can. 2016;1(3):1–16.
  31. Centers for Disease Control and Prevention. ACIP Recommendations. Updated March 6, 2024. Accessed April 18, 2024. Available at: https://www.cdc.gov/vaccines/acip/recommendations.html.
Valneva Canada Inc.
Commercial Operations
3535 Saint-Charles Blvd., Suite 600
Kirkland (Montreal), Quebec H9H 5B9, Canada
Telephone: 514-630-6999